Spectral AI, Inc. Class A Common Stock
MDAIStock
$1.65−39.86%52W
Market Cap$52.51M
P/E—
Div yield—
Beta1.18
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-8.26%
Price vs S&P 500 (4W)-7.74%
VGM Score27.91
Market Capitalization$52.51M
Earnings Surprise History
Q1 26-0.11est. -0.09
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.25
4.25
4.25
4.25
Industry Peers — Surgical & Medical Instruments(141)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MDAISpectral AI, Inc. Class A Common Stock | D | F | C | $1.65 |
| SYKStryker Corporation | C | C | D | $331.20 |
| MMM3M Company | C | F | B | $161.77 |
| BSXBoston Scientific Corp. | C | B | F | $44.62 |
| MDLNMedline Inc. Class A common stock | C | D | D | $41.11 |
| BDXBecton, Dickinson and Co. | B | C | B | $159.93 |
| DXCMDexCom, Inc. | C | B | C | $77.98 |
| RMDResMed Inc. | C | B | D | $202.76 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | $362.44 |
| SOLVSolventum Corporation | C | D | B | $81.70 |
| PENPenumbra, Inc. | F | C | B | $319.60 |
About
Spectral AI develops DeepView, an AI-powered diagnostic system that uses proprietary algorithms and multispectral imaging to assess tissue damage and wound healing. The system has received FDA Breakthrough Device Designation and delivers healing assessments in seconds, enabling physicians to make faster, more accurate treatment decisions. By detecting damage invisible to the naked eye, DeepView aims to improve wound treatment outcomes and streamline clinical workflows.